Raymond James Boosts HLS Therapeutics (TSE:HLS) Price Target to C$5.00

HLS Therapeutics (TSE:HLS) had its price target increased by Raymond James from C$4.00 to C$5.00 in a research note issued to investors on Friday,BayStreet.CA reports. Raymond James’ price target suggests a potential upside of 42.86% from the stock’s previous close.

Separately, Stifel Nicolaus lowered their price objective on shares of HLS Therapeutics from C$3.75 to C$3.25 in a research note on Tuesday, August 13th.

HLS Therapeutics Stock Performance

Shares of HLS stock traded up C$0.19 on Friday, hitting C$3.50. The company had a trading volume of 7,061 shares, compared to its average volume of 26,986. HLS Therapeutics has a twelve month low of C$3.00 and a twelve month high of C$5.48. The company has a quick ratio of 1.01, a current ratio of 2.02 and a debt-to-equity ratio of 100.44. The firm has a market cap of C$111.27 million, a P/E ratio of -3.47 and a beta of 1.07. The company has a 50-day moving average price of C$3.54 and a 200-day moving average price of C$3.51.

HLS Therapeutics Company Profile

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company’s product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.